メタ情報
| meta description平均長 | 61.42 |
|---|
| OGPありページ数 | 19 |
|---|
| Twitterカードありページ数 | 19 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 70 |
|---|
| ページあたり内部リンク平均 | 39 |
|---|
連絡先候補（Contacts）
このデータの閲覧には会員登録が必要になります。会員登録
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| PGx | 1 |
| transfection | 0.650347 |
| drug | 0.622072 |
| cells | 0.599944 |
| cell | 0.56552 |
| genes | 0.466623 |
| well | 0.466623 |
| phase | 0.452416 |
| technology | 0.42414 |
| research | 0.399963 |
| our | 0.38969 |
| Phase | 0.368421 |
| responder | 0.368421 |
| solid | 0.367588 |
| was | 0.339312 |
| gene | 0.32363 |
| Innovation | 0.32363 |
| customers | 0.32363 |
| Cellular | 0.315789 |
| responding | 0.315789 |
| providing | 0.299972 |
| will | 0.299972 |
| high | 0.299972 |
| not | 0.299972 |
| non | 0.28276 |
| Shinjuku | 0.28276 |
| Proposal | 0.266642 |
| format | 0.263158 |
| applicable | 0.263158 |
| wide | 0.263158 |
| responsible | 0.263158 |
| population | 0.263158 |
| their | 0.242723 |
| 東京都新宿区西新宿3 | 0.242723 |
| experiments | 0.233312 |
| have | 0.232677 |
| efficiency | 0.210526 |
| strains | 0.210526 |
| primary | 0.210526 |
| adherent | 0.210526 |
| combination | 0.210526 |
| clinical | 0.210526 |
| network | 0.210526 |
| identify | 0.210526 |
| patients | 0.210526 |
| populations | 0.210526 |
| sub | 0.210526 |
| 以下 | 0.210526 |
| services | 0.199981 |
| development | 0.199981 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| 事業内容 | 会社概要 | 3.210986 | 28 |
| phase | solid | 3.188547 | 50 |
| General | Meeting | 2.938836 | 24 |
| お知らせ | 事業内容 | 2.89212 | 21 |
| General | Ordinary | 2.887627 | 24 |
| Meeting | Shareholders | 2.846157 | 22 |
| CytoPathfinder | Inc | 2.838427 | 39 |
| Shinjuku | Tokyo | 2.763363 | 25 |
| お知らせ | 会社概要 | 2.757868 | 21 |
| 東京都新宿区西新宿3 | 第2太閤ビル | 2.643219 | 18 |
| companies | pharmaceutical | 2.566581 | 16 |
| life | sciences | 2.566581 | 16 |
| Ryuji | Yamamoto | 2.566581 | 16 |
| CEO | Yamamoto | 2.566581 | 16 |
| originally | proposed | 2.566581 | 16 |
| approved | originally | 2.433265 | 16 |
| General | Shareholders | 2.385053 | 18 |
| Nishishinjuku | Shinjuku | 2.368933 | 18 |
| high | throughput | 2.347861 | 20 |
| Meeting | Ordinary | 2.337868 | 18 |
| rate | success | 2.337369 | 12 |
| down | narrow | 2.337369 | 12 |
| Office | Square | 2.337369 | 12 |
| Financial | Statements | 2.337369 | 12 |
| Fiscal | Year | 2.337369 | 12 |
| Building | Shinjuku | 2.327889 | 19 |
| Cellular | PGx | 2.267873 | 26 |
| Japan | Tokyo | 2.191022 | 16 |
| function | loss | 2.190668 | 12 |
| February | held | 2.190668 | 12 |
| February | resolution | 2.190668 | 12 |
| Approval | Financial | 2.190668 | 12 |
| Building | Nishishinjuku | 2.18791 | 14 |
| approved | was | 2.154048 | 20 |
| gene | network | 2.152463 | 16 |
| Approval | Proposal | 2.152463 | 16 |
| 初台駅 | 北口徒歩10分 | 2.127482 | 10 |
| format | well | 2.111098 | 19 |
| discovery | drug | 2.108348 | 28 |
| Contributing | people | 2.10702 | 8 |
| わたしたちが目指すもの | サイエンスとイノベーションで世界の人々の健康に貢献すること | 2.10702 | 8 |
| Center | Innovation | 2.079289 | 14 |
| screening | throughput | 2.076878 | 12 |
| Building | Square | 2.076878 | 12 |
| non | responder | 2.062119 | 19 |
| California | School | 2.059406 | 8 |
| Innovation | Japan | 2.049792 | 16 |
| CEO | Ryuji | 2.043967 | 12 |
| Center | Japan | 2.043967 | 12 |
| develop | will | 2.019147 | 16 |